Advertisement

Topics

European Regulatory Committee Recommends Rejecting Puma Biotechnology’s Breast Cancer Medicine

19:00 EST 22 Feb 2018 | BioSpace

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) offered a negative opinion on Puma Biotechnology’s application for neratinib for breast cancer.

Original Article: European Regulatory Committee Recommends Rejecting Puma Biotechnology’s Breast Cancer Medicine

NEXT ARTICLE

More From BioPortfolio on "European Regulatory Committee Recommends Rejecting Puma Biotechnology’s Breast Cancer Medicine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioscience
Bioscience - any of the sciences that deal with living organisms.  The study of the nature, behavior, and uses of living organisms as applied to biology. Any of the branches of natural science dealing with living things, such as their structure, b...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...